Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae

Abstract The diagnosis of postacute sequelae of coronavirus disease 2019 (PASC) poses an ongoing medical challenge. To identify biomarkers associated with PASC we analyzed plasma samples collected from PASC and coronavirus disease 2019 patients to quantify viral antigens and inflammatory markers. We...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 76; no. 3; pp. e487 - e490
Main Authors Swank, Zoe, Senussi, Yasmeen, Manickas-Hill, Zachary, Yu, Xu G, Li, Jonathan Z, Alter, Galit, Walt, David R
Format Journal Article
LanguageEnglish
Published US Oxford University Press 08.02.2023
Subjects
Antigens, Viral - blood
Antigens, Viral - immunology
Biomarkers - blood
Brief Report
COVID-19 - blood
COVID-19 - complications
COVID-19 - immunology
Disease Progression
Editor's Choice
Humans
Post-Acute COVID-19 Syndrome - blood
Post-Acute COVID-19 Syndrome - diagnosis
Post-Acute COVID-19 Syndrome - immunology
SARS-CoV-2
Spike Glycoprotein, Coronavirus - blood
COVID-19
long COVID
SARS-CoV-2 antigens
post-acute sequelae of COVID-19 (PASC)
spike
Online AccessGet full text

Cover

More Information
Summary:Abstract The diagnosis of postacute sequelae of coronavirus disease 2019 (PASC) poses an ongoing medical challenge. To identify biomarkers associated with PASC we analyzed plasma samples collected from PASC and coronavirus disease 2019 patients to quantify viral antigens and inflammatory markers. We detect severe acute respiratory syndrome coronavirus 2 spike predominantly in PASC patients up to 12 months after diagnosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Potential conflicts of interest. D. W. has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the single molecule array technology, a founder of the company and also serves on its Board of Directors. D. W.'s interests were reviewed and are managed by Brigham and Women's Hospital and Partners Healthcare in accordance with their conflict of interest policies. He also holds stock and stock options for Quanterix Corporation. G. A. reports grants or contracts from Biontech, Merck, and BMS; consulting fees from Sanofi and Moderna, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK and Astrazeneca; patents from REFORM—Antibody Engineering—MGH; CAPRISA CAP276 HIV monoclonal DSMB; is a part of the Sanofi Scientific Advisory Board; and holds stock or stock options for Systems Seromyx and Leyden Labs. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciac722